These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 810614

  • 21. [Note on a clinical trial of rifampicin in the treatment of pulmonary tuberculosis].
    Robustelli Pisani F.
    G Ital Mal Torace; 1969; ():Suppl 2:85+. PubMed ID: 4982436
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Incidence and clinical significance of visible but not viable bacilli in patients with pulmonary tuberculosis].
    Krychniak W, Araszkiewicz W, Zych D, Janowiec M, Pelczarska B.
    Gruzlica; 1975 Sep; 43(9):785-92. PubMed ID: 808444
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [A study of prevalence of resistance to major drugs among newly admitted pulmonary tuberculosis patients in 1972. Part 2. Studies on the factors related to the prevalence of drug resistance (author's transl)].
    Gomi J, Chiba Y, Yanagisawa K.
    Kekkaku; 1975 Feb 15; 50(2):55-62. PubMed ID: 815707
    [No Abstract] [Full Text] [Related]

  • 33. [Selection of the method of treatment for noncavitary tuberculosis cases with negative sputum for more than 6 months based on culture findings of tubercule bacilli from resected specimens (author's transl)].
    Sato M.
    Kekkaku; 1976 Aug 15; 51(8):329-36. PubMed ID: 824492
    [No Abstract] [Full Text] [Related]

  • 34. [Dynamics of the release of bacilli and the closing of caverns in newly identified tuberculosis patients undergoing different chemotherapeutic regimens].
    Muratov VV, Pashkov IuN, Pospelov VV.
    Probl Tuberk; 1981 Dec 15; (12):30-4. PubMed ID: 6801646
    [No Abstract] [Full Text] [Related]

  • 35. [Chemotherapy of patients with chronic destructive pulmonary tuberculosis in cases of mycobacterial resistance to rifampicin and isoniazid].
    Bialik IB, Klimenko MT.
    Klin Med (Mosk); 1985 Dec 15; 63(12):42-7. PubMed ID: 3937942
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Clinical results of retreatment using rifampicin for more than 12 months for pulmonary tuberculosis (author's transl)].
    Urakami E, Nagasawa S.
    Kekkaku; 1973 Sep 15; 48(9):411-6. PubMed ID: 4772413
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.